ideasIdea
One standing umbrella trial for all rare cancers in a country
Rare cancers together are a fifth of all cancers, but each is too small for its own trial. One permanent trial with many arms would give all of them a route.
Rare cancer patients face a structural problem: no single disease supports a trial, so most receive off-label therapy with no data capture. A standing national umbrella — one master protocol, molecular screening for all comers, arms opened by mechanism, shared infrastructure and Bayesian analysis — has precedent in genomically driven platforms and in national molecular screening programmes, but is rarely made permanent or made the default route.
Hypothesis
A permanent rare cancer umbrella platform enrols over 2,000 patients per year in a mid-sized country, delivers analysable results for at least ten mechanism-defined arms in five years, and reduces the cost per evaluable patient by half.
Rationale
Shared control arms, shared screening and shared infrastructure are the only ways to make small populations statistically and economically tractable, as demonstrated by platform trials in genomic screening programmes and in paediatric oncology consortia.
What would test it
Fund a three-year platform pilot with pre-specified success metrics on enrolment, arms completed and cost per evaluable patient, compared with the preceding period of standalone rare cancer trials.
Maturity
being tested at scale
Who has to act
policy
Cost to try
Large (over $50M)
Years to first evidence
5
Bottlenecks it attacks
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.